Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Read More

Overview

Feature Articles

Latest Prostate Cancer News and Research

In a first, Trump and GOP-led Congress prepare to swell ranks of U.S. uninsured

In a first, Trump and GOP-led Congress prepare to swell ranks of U.S. uninsured

Study reveals how FOXA1 mutations drive prostate cancer and therapy resistance

Study reveals how FOXA1 mutations drive prostate cancer and therapy resistance

Harnessing saliva for precision medicine and early disease diagnosis

Harnessing saliva for precision medicine and early disease diagnosis

Dual threats from Trump and GOP imperil nursing homes and their foreign-born workers

Dual threats from Trump and GOP imperil nursing homes and their foreign-born workers

Fusion genes found to be pivotal players in cancer development

Fusion genes found to be pivotal players in cancer development

Uncovering hidden disease clues with nanoparticles and AI

Uncovering hidden disease clues with nanoparticles and AI

New DNA test predicts chemotherapy resistance in cancer patients

New DNA test predicts chemotherapy resistance in cancer patients

Inflammation drives early prostate cancer through cellular reprogramming

Inflammation drives early prostate cancer through cellular reprogramming

TTUHSC researchers seek to understand TBX2's role in bone metastasis of prostate cancer

TTUHSC researchers seek to understand TBX2's role in bone metastasis of prostate cancer

Glucocorticoid receptor plays dual role in prostate cancer progression

Glucocorticoid receptor plays dual role in prostate cancer progression

Study reveals the genetic underpinnings of a rare and aggressive ovarian cancer

Study reveals the genetic underpinnings of a rare and aggressive ovarian cancer

Ending unnecessary cancer screenings can take over a decade

Ending unnecessary cancer screenings can take over a decade

Overexpression of two long non-coding RNAs identified in gastric cancer

Overexpression of two long non-coding RNAs identified in gastric cancer

Bone medications and steroids linked to increased risk of jaw disease

Bone medications and steroids linked to increased risk of jaw disease

Terbium therapy shows promise in fighting lymphoma

Terbium therapy shows promise in fighting lymphoma

Researchers identify gene driving aggressive prostate cancer

Researchers identify gene driving aggressive prostate cancer

New trial offers hope for men with aggressive prostate cancer

New trial offers hope for men with aggressive prostate cancer

New AI test identifies prostate cancer patients who benefit from abiraterone

New AI test identifies prostate cancer patients who benefit from abiraterone

New genetic mutation linked to increased prostate cancer risk in Ashkenazi Jewish men

New genetic mutation linked to increased prostate cancer risk in Ashkenazi Jewish men

Diabetes drug shows potential in slowing prostate cancer progression

Diabetes drug shows potential in slowing prostate cancer progression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.